首页|莫西沙星、布地奈德联合无创通气对社区获得性肺炎伴呼吸衰竭患者通气能力和预后的影响

莫西沙星、布地奈德联合无创通气对社区获得性肺炎伴呼吸衰竭患者通气能力和预后的影响

扫码查看
目的 探讨莫西沙星、布地奈德联合无创通气对社区获得性肺炎(CAP)伴呼吸衰竭(RF)患者通气能力和预后的影响.方法 选取 2020 年1月至2021 年12 月收治的78 例CAP伴RF患者为研究对象,按照抛硬币法将其分为对照组和观察组,每组 39 例.对照组行常规方案和无创通气治疗,观察组在对照组基础上联合莫西沙星、布地奈德治疗.比较两组的治疗效果.结果 治疗后,观察组的血氧饱和度(SaO2)和血氧分压(PaO2)高于对照组,二氧化碳分压(PaCO2)低于对照组(P<0.05).治疗后,观察组的第 1 秒用力呼气容积(FEV1)、用力肺活量(FVC)和肺动态顺应性(Cdyn)高于对照组(P<0.05).治疗后,观察组的半胱氨酸白三烯(CysLTs)、可溶性细胞间黏附分子-1(sICAM-1)和C-反应蛋白(CRP)水平低于对照组(P<0.05).观察组的治疗总有效率高于对照组(P<0.05).两组的不良反应总发生率无显著差异(P>0.05).结论 莫西沙星、布地奈德联合无创通气治疗CAP伴RF可有效改善患者的肺通气能力,减轻炎症反应,促进病情恢复.
Effects of moxifloxacin and budesonide combined with non-invasive ventilation on ventilation capacity and prognosis in patients with community-acquired pneumonia and respiratory failure
Objective To investigate the effects of moxifloxacin and budesonide combined with non-invasive ventilation on ventilation capacity and prognosis in patients with community-acquired pneumonia(CAP)and respiratory failure(RF).Methods A total of 78 patients with CAP and RF admitted from January 2020 to December 2021 were selected as the research objects,and the patients were divided into control group and observation group according to coin tossing method,with 39 cases in each group.The control group was treated with conventional regimen and non-invasive ventilation,the observation group was treated with moxifloxacin and budesonide on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the blood oxygen saturation(SaO2)and partial pressure of oxygen(PaO2)in the observation group were higher than those in the control group,and the partial pressure of carbon dioxide(PaCO2)was lower than that in the control group(P<0.05).After treatment,the forced expiratory volume in one second(FEV1),forced vital capacity(FVC)and pulmonary dynamic compliance(Cdyn)in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of cysteinyl leukotrienes(CysLTs),soluble intracellular adhesion molecule-1(sICAM-1)and C-reactive protein(CRP)in the observation group were lower than those in the control group(P<0.05).The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The moxifloxacin and budesonide combined with non-invasive ventilation in the treatment of CAP and RF can effectively improve the pulmonary ventilation capacity of patients,reduce the inflammatory reaction and promote the recovery of symptoms.

community-acquired pneumoniarespiratory failuremoxifloxacinbudesonidenon-invasive ventilationventilation capacity

黄义斌、赵亮

展开 >

西乡县人民医院呼吸内科,陕西 汉中,723500

汉中市中心医院呼吸与危重症医学科一病区,陕西 汉中,723000

社区获得性肺炎 呼吸衰竭 莫西沙星 布地奈德 无创通气 通气能力

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(24)